Group One Trading’s Viridian Therapeutics VRDN Stock Holding History

Group One Trading’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-61,500	Closed	-$1.2M	–	8600
2026 Q1	$1.2M	Buy	+61,500	New	+$1.83M	﹤0.01%	2540
2025 Q4	–	Sell	-5,000	Closed	-$108K	–	9251
2025 Q3	$108K	Sell	5,000 -4,600	-48%	-$83K	﹤0.01%	5273
2025 Q2	$134K	Buy	9,600 +7,700	+405%	+$105K	﹤0.01%	4714
2025 Q1	$25.6K	Sell	1,900 -90,500	-98%	-$1.54M	﹤0.01%	5651
2024 Q4	$1.77M	Buy	92,400 +42,100	+84%	+$915K	﹤0.01%	2034
2024 Q3	$1.14M	Buy	50,300 +34,900	+227%	+$571K	﹤0.01%	2183
2024 Q2	$200K	Buy	+15,400	New	+$213K	﹤0.01%	3380
2024 Q1	–	Sell	-100	Closed	-$2.18K	–	8031
2023 Q4	$2.18K	Sell	100 -5,100	-98%	-$80.5K	﹤0.01%	6794
2023 Q3	$79.8K	Sell	5,200 -24,800	-83%	-$473K	﹤0.01%	4658
2023 Q2	$714K	Buy	+30,000	New	+$769K	﹤0.01%	2664
2022 Q4	–	Sell	-100	Closed	-$2K	–	8158
2022 Q3	$2K	Buy	+100	New	+$1.8K	﹤0.01%	7215

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Group One Trading's VRDN Position: Q3 2026 in Review

Group One Trading opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 1,195 shares worth $24.6K. The stake represents ﹤0.01% of the portfolio and ranks #5735 among its holdings. This is a return to the name: Group One Trading previously reported a position in VRDN as recently as Q1 2026.

Group One Trading first reported a position in VRDN in Q2 2023 and has held it in 9 quarters since. The position peaked at $927K in Q3 2024. 121 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

Group One Trading held 1,195 shares of Viridian Therapeutics worth $24.6K as of Q3 2026.
Viridian Therapeutics was a new Group One Trading position in Q3 2026.
Viridian Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #5735 holding.
Group One Trading first reported a position in Viridian Therapeutics in Q2 2023 and has held it in 9 quarters since.
Group One Trading's Viridian Therapeutics position peaked at $927K in Q3 2024.
121 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.